Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2020-04-07 Regulatory Filings
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Bard1 and Sienna Cancer Diagnostics announce merger 74 pages 1.1MB
Regulatory Filings
2020-04-07 English
SDX: Cancer diagnostic coys Sienna and BARD1 announce merger 74 pages 1.0MB
Regulatory Filings
2020-04-07 English
BARD1 Signs Contract with Griffith University 2 pages 124.3KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing that BARD1 Life Sciences Limited has signed a Consultancy and Commercial Research Agreement with Griffith University. It describes the nature of the agreement and the strategic benefits for the company. There is no financial data, no regulatory filing references, no voting results, no management or board changes, no earnings or interim report data, and no mention of any report being attached or published. The content is a corporate announcement about a commercial research agreement, which fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-04-01 English
Half Yearly Report and Accounts 22 pages 752.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'APPENDIX 4D AND HALF-YEAR REPORT' and provides detailed financial results for the half-year ended 31 December 2019. It includes comprehensive financial data such as net loss, cash balance, capital raising details, operational review, directors' report, consolidated financial statements, and auditor's review report. The presence of detailed financial statements and notes confirms it is a substantive financial report for a period shorter than a full fiscal year. The document is about 15,000 characters long, indicating it is the full report, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-02-24 English
Appendix 4C Quarterly Cashflow Report 6 pages 315.2KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'QUARTERLY CASHFLOW REPORT' and references 'Appendix 4C Quarterly Cashflow Report' for the quarter ended 31 December 2019. It is prepared in accordance with ASX Listing Rule 4.7B, which mandates quarterly cash flow reporting for listed entities in Australia. The document contains detailed cash flow statements including operating, investing, and financing activities, as well as reconciliation of cash and cash equivalents. It also includes estimated cash outflows for the next quarter and compliance statements. The length of the document (over 10,000 characters) and the presence of substantive financial data confirm it is a financial report rather than a mere announcement. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and analysis. Therefore, the correct classification is IR with high confidence. Q4 2019
2020-01-29 English
Director Appointment 2 pages 116.9KB
Board/Management Information Classification · 100% confidence The document is an announcement about the appointment of a new Non-Executive Director to the company's board. It details the background and qualifications of Professor Allan Cripps and the strategic importance of his appointment. There is no financial data, no discussion of financial results, no mention of shareholder votes, no regulatory filings, and no report publication. The content focuses solely on a change in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is about 5938 characters, which is sufficient for a detailed announcement but does not contain financial statements or other report types.
2020-01-22 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.